Stocktoria
RHYTHM PHARMACEUTICALS, INC. RYTM
RHYTHM PHARMACEUTICALS, INC. (RYTM) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $189.8M at a -103.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.89 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-16 | Canaccord Genuity | Buy (main) |
| 2026-06-15 | Wells Fargo | Overweight (main) |
| 2026-05-07 | Canaccord Genuity | Buy (main) |
| 2026-05-06 | RBC Capital | Outperform (main) |
| 2026-05-06 | Wells Fargo | Overweight (main) |
| 2026-03-23 | HC Wainwright & Co. | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.752 |
| Retained earnings / assets | -2.815 |
| EBIT / assets | -0.4 |
| Equity / liabilities | 0.662 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RYTM | RHYTHM PHARMACEUTICALS, INC. | 5/9 | -6.24 | — | +45.8% |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | 1/9 | 1.29 | — | -28.3% |
| STOK | Stoke Therapeutics, Inc. | 4/9 | 5.29 | — | +404.5% |
| CYRX | Cryoport, Inc. | 4/9 | 0.96 | 10.3 | +12.4% |
| PHAT | Phathom Pharmaceuticals, Inc. | 4/9 | — | — | +216.9% |
| SNDX | Syndax Pharmaceuticals Inc | 1/9 | -7.54 | — | +627.8% |
| AMRN | AMARIN CORP PLCUK | 5/9 | -2.07 | — | -6.5% |
About RHYTHM PHARMACEUTICALS, INC.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
FAQ
Is RYTM financially healthy?
RHYTHM PHARMACEUTICALS, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does RYTM pay a dividend?
No, RHYTHM PHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is RYTM?
In FY2025, RHYTHM PHARMACEUTICALS, INC. had a net margin of -103.6% and a return on equity of -141.3%.
What is the analyst price target for RYTM?
The average Wall-Street price target for RHYTHM PHARMACEUTICALS, INC. is $139.47, about 18.6% above the recent price, from 15 analysts (consensus: strong buy).
Is RYTM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on RHYTHM PHARMACEUTICALS, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.